High Melphalan Exposure Increases the Risk of Graft-Versus-Host Disease in Pediatric Patients Undergoing Alpha-Beta T-Cell Depleted Haploidentical Transplantation

High melphalan exposure predicted by a validated population PK model is associated with an increased likelihood of developing ES and subsequently acute and chronic GVHD. Given that a substantial number of patients already require adjustment of standard BSA-based dosing for young age or obesity, a prospective trial of model-based dosing to individualize melphalan exposure is warranted to confirm these results.

Authors

Institutions

Publication Details

Journal
Transplantation and Cellular Therapy
Published
2025-04-05
DOI
https://doi.org/10.1016/j.jtct.2025.03.020
Citations
2
Primary Topic
Hematopoietic Stem Cell Transplantation
Type
article
Field-Weighted Citation Impact
3.54

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

High Melphalan Exposure Increases the Risk of Graft-Versus-Host Disease in Pediatric Patients Undergoing Alpha-Beta T-Cell Depleted Haploidentical Transplantation

Michael A. Pulsipher, William C. Temple, Geoffrey Cheng, James N. Huang et al.
2 citations
Transplantation and Cellular Therapy
Hematopoietic Stem Cell Transplantation
3.54
article

High Melphalan Exposure Increases the Risk of Graft-Versus-Host Disease in Pediatric Patients Undergoing Alpha-Beta T-Cell Depleted Haploidentical Transplantation

Michael A. Pulsipher, William C. Temple, Geoffrey Cheng, James N. Huang, Gabriel Salinas Cisneros, Lena E. Winestone, Christopher C. Dvorak, Serine Avagyan, Soohee Cho, Kristin A. Shimano, Paibel Aguayo‐Hiraldo, Sandhya Kharbanda, Ron J. Keizer, Janel Long-Boyle, Nahal Lalefar, Christine S. Higham, Philip T. Pauerstein, Julia Chu
article en
2 citations

Abstract

High melphalan exposure predicted by a validated population PK model is associated with an increased likelihood of developing ES and subsequently acute and chronic GVHD. Given that a substantial number of patients already require adjustment of standard BSA-based dosing for young age or obesity, a prospective trial of model-based dosing to individualize melphalan exposure is warranted to confirm these results.

Transplantation and Cellular TherapyVol. 31(6)
Primary Children's Hospital (US), Children's Hospital of Los Angeles (US), University of California, San Francisco (US), Huntsman Cancer Institute (US), IDinsight (US), International Neuromodulation Society (US)
National Institutes of Health, National Heart, Lung, and Blood Institute, National Cancer Institute
Zero hunger
Openalex Percentile: Top 9%
Hematopoietic Stem Cell Transplantation
3.54
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.